



(51) International Patent Classification:

A61K 39/095 (2006.01) A61K 33/08 (2006.01)
A61K 39/39 (2006.01) A61K 33/42 (2006.01)
A61K 31/4375 (2006.01) A61K 31/04 (2006.01)
A61K 31/66 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/IB2010/002386

(22) International Filing Date:

1 September 2010 (01.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/239,156 2 September 2009 (02.09.2009) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SINGH, Manmohan** [US/US]; c/o Novartis Vaccines And Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608 (US). **SKIBINSKI, David** [IT/IT]; c/o Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **CIANETTI, Simona** [IT/

IT]; c/o Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **DORO, Francesco** [IT/IT]; c/o Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **JAIN, Siddhartha** [IN/US]; c/o Novartis Vaccines And Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608 (US).


(74) Agents: **MARSHALL, Cameron, John** et al.; Carpmaels & Ransford, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) Title: IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS

Figure 3

(57) Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

5 May 2011

Published:

— *with international search report (Art. 21(3))*